Evidence map›Paper›PMID 25636341›Full record

Trial reportBlood2015

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.

Elisabeth Pasquier, Luc de Saint Martin, Caroline Bohec, Céline Chauleur, Florence Bretelle, Gisèle Marhic, Grégoire Le Gal, Véronique Debarge, Frédéric Lecomte, Christine Denoual-Ziad and 4 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00740545 (Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées), which is not on this map. Cited by 43 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 10 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00740545 phase3terminatednot on this map

Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées

TypeinterventionalSponsorUniversity Hospital, BrestRan2007 to 2014Enrolled258ConditionsAlive and Viable BirthsArmsenoxaparine 40 mg daily, placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 10 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Australasian recurrent pregnancy loss clinical management guideline 2024, part II.The Australian & New Zealand journal of obstetrics & gynaecology · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Weekly changes in serumThe Journal of international medical research · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Elisabeth PasquierEA 3878 Groupe d'Etude de la Thrombose de Bretagne Occidentale, Department of Internal Medicine and Chest Diseases, Brest University Hospital, La Cavale Blanche Hospital, Brest, France;ORCID http://orcid.org/0000-0002-5849-0204
Luc de Saint MartinEA 3878 Groupe d'Etude de la Thrombose de Bretagne Occidentale, Department of Internal Medicine and Chest Diseases, Brest University Hospital, La Cavale Blanche Hospital, Brest, France;
Caroline BohecDivision of Gynaecology, François Mitterand Hospital, Pau, France;
Céline ChauleurDivision of Gynaecology, Saint Etienne University Hospital, Saint Etienne, France;
Florence BretelleDivision of Gynaecology, Université de la Méditerranée, Hôpital Nord, Marseille, France;
Gisèle MarhicCentres d'Investigation Clinique-INSERM 1412, La Cavale Blanche Hospital, Brest, France;
Grégoire Le GalEA 3878 Groupe d'Etude de la Thrombose de Bretagne Occidentale, Centres d'Investigation Clinique-INSERM 1412, La Cavale Blanche Hospital, Brest, France;
Véronique DebargeDivision of Gynaecology, Lille University Hospital, Lille, France;
Frédéric LecomteDivision of Internal Medicine, Bretagne Sud Hospital, Lorient, France;
Christine Denoual-ZiadDivision of Gynaecology, Caen University Hospital, Clemenceau Hospital, Caen, France;
Véronique Lejeune-SaadaDivision of Gynaecology, Paris University Hospital, Necker Hospital, Paris, France;
Serge DouvierDivision of Gynaecology, Dijon University Hospital, Complexe du Bocage, Dijon, France; and.
Michel HeisertDivision of Gynaecology, Groupe Hospitalier du Sud de la Réunion, Saint Pierre, France.
Dominique MottierEA 3878 Groupe d'Etude de la Thrombose de Bretagne Occidentale, Centres d'Investigation Clinique-INSERM 1412, La Cavale Blanche Hospital, Brest, France;
Inserm · FRUniversité de Bretagne Occidentale · FRAssociation François Aupetit · FRCentre Hospitalier de Bretagne Sud · FRCentre Hospitalier Universitaire de La Réunion · FRCentre Hospitalier Universitaire de Saint-Étienne · FRHôpital Georges-Clemenceau · FRHôpital Nord · FRMaison des Sciences sociales et des Humanités de Dijon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is common practice in many centers to offer antithrombotic medications to women with unexplained recurrent miscarriage, in the presence or absence of inherited thrombophilia. Although no benefit of aspirin vs placebo has been clearly demonstrated, a double-blind placebo-controlled trial on the effect of low-molecular-weight heparin is lacking. We enrolled 258 pregnant women with a history of unexplained recurrent miscarriage (≥2 consecutive miscarriages before 15 weeks' gestation) and a negative thrombophilia workup. They were randomly assigned to receive one daily subcutaneous injection of enoxaparin 40 mg or placebo until 35 weeks' gestation. We included 256 women (mean age 32 years, ≥3 miscarriages: 72%; mean gestational age 39 days of amenorrhea) in the intention-to-treat analysis; 66.6% of 138 who received enoxaparin had a live birth vs 72.9% of 118 who received placebo. The absolute difference was -6% (95% CI, -17.1 to 5.1), excluding a 10% increase in the rate of live-birth on enoxaparin (P = .34). In this first randomized, double-blind, placebo-controlled trial, enoxaparin (40 mg once daily) did not improve the chance of a live birth in nonthrombophilic women with unexplained recurrent miscarriage. This trial is registered at www.ClinicalTrials.gov as #NCT00740545 and the French National Health and Drug Safety Agency (EudraCT #2006-003350-18).

Indexed as

Abortion, HabitualAdultAnticoagulantsDouble-Blind MethodEnoxaparinFemaleFollow-Up StudiesGestational AgeHeparin, Low-Molecular-WeightHumansLive BirthPregnancyPregnancy ComplicationsPrognosisAnticoagulantsEnoxaparinHeparin, Low-Molecular-Weight

Identifiers

PMID25636341
PMCPMC4432556
OpenAlexW1986150666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.